ViGenCell Inc.
Developing T-cell immune therapies to treat cancer and other incurable diseases.
308080 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 금천구 가산로9길 66 더리즌밸리 지식산업센터(가산동), 서울특별시
- Website:
- https://www.vigencell.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
ViGenCell Inc. is a biotechnology company specializing in the research and development of immune cell therapies. The company develops novel treatments for cancers and other incurable diseases, aiming to prolong life expectancy and enhance patient quality of life. Its core technology includes ViTier, a proprietary T-cell therapy platform that employs antigen-specific killer T cells to target and eliminate pathogens or tumor cells. Founded in 2013 as the first subsidiary of the Catholic University Technology Holdings, ViGenCell leverages clinically validated research to advance its therapeutic pipeline.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for ViGenCell Inc. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
Automate Your Workflow. Get a real-time feed of all ViGenCell Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for ViGenCell Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
